胰岛素与利拉鲁肽联用对2型糖尿病患者血糖相关指标改善作用的疗效分析

Clinical Efficacy of Plasma Glucose Related Indicators Improved by Using Insulin and Liraglutide in Patient with Type 2 Diabetes Mellitus

目的:分析胰岛素与利拉鲁肽对2型糖尿病(T2DM)患者血糖相关指标改善作用的疗效。方法:选取2015年1月—2016年1月间收治的T2DM患者60例,将其分为观察组和对照组,每组30例;对照组患者给予胰岛素治疗,观察组患者在对照组基础上加用拉鲁肽治疗,评价治疗前与治疗3月后两组患者血糖各指标的改善作用和相关体症的改善情况。结果:两组患者治疗后空腹血糖、餐后2 h血糖、糖化血红蛋白均低于治疗前(P<0.05);治疗后观察组患者体质量、腹围、BMI以及每日胰岛素用量均高于治疗前(P<0.05);而HOMA-IR低于治疗前(P<0.05);观察组患者治疗后体质量、腹围、BMI值、HOMA-IR和每日胰岛素用量指标均低于治疗前(P<0.05)。结论:胰岛素与利拉鲁肽联用治疗T2DM患者的降糖效果较为显著,同时可以降低患者体质量,减少每日胰岛素的用量,对血糖各指标的改善作用和相关体症的改善情况较为显著。

Objective： To analyze the clinical efficacy of plasma glucose related indicators improved by using insulin and liraglutide in patient with type 2 diabetes mellitus（T2DM）. Methods： 60 patients with T2DM were randomly divided into observation group（n=30） and control group（n=30） between Jahuary 2015 and January 2016. Observation group were treated with insulin and liraglutide and the control group were treated with insulin. Three months after treatment treatment effects were observed. Results： After treatment, fasting blood glucose, postprandial 2h blood glucose, glycosylated hemoglobin compared with before treatment, the difference was statistically significant （P〈0.05）, but the difference between the two groups was not statistically significant （P〉0.05）. Insulin therapy patients, weight, waist circumference, BMI and daily insulin dose increased than before treatment, relevant comparative indicators were statistically significant （P〈0.05）; HOMA-IR compared with before treatment, there was statistical significance （P〈0.05）. In liraglutide treatment body mass, waist circumference, BMI values, insulin resistance index （HOMA-IR）, and daily insulin dose indicator lower than before treatment, and the differences were statistically significant （P〈0.05）. Two groups of patients after treatment in boby mass, abdominal circumference, BMI values, insulin resistance index （HOMA-IR） and daily insulin dose indicators were lower and the difference was statistically significant （P〈0.05）. Conclusion： Hypoglycemic clinical efficacy is significant in using insulin and liraglutide in patient with T2DM, and on reducing patient body mass the daily dosage of insulin is reduced, having a borer therapeutic effect.